Highlights of weekly biotech stock moves

Alimera Sciences Inc. (NASDAQ:ALIM) gained $0.60 to $7.20 last week after resubmitting an NDA to FDA for Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). The company said the resubmission addresses issues raised by FDA in an October complete response letter and contains a safety update. Alimera markets Iluvien in Europe.

Alimera has rights to Iluvien from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), which was off $0.55 (12%) to $3.89 on NASDAQ and off A$0.44 to A$4 in Australia for the week...